About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NVS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer
NCT07908667 · Extensive-stage Small Cell Lung Cancer
TRB191
NVS
Novartis Pharmaceuticals
Phase 1Recruiting
was not yet recruiting
120Jul 30, 2030Registry ↗
Nov 13, 2026A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofi…
Pelabresib, Ruxolitinib
NVS
Novartis Pharmaceuticals
Phase 3Recruiting460May 17, 2028Registry ↗
Nov 13, 2026TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. D…
NCT07190300 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Tulmimetostat, Darolutamide
NVS
Novartis Pharmaceuticals
Phase 1/2Recruiting181Aug 2, 2032Registry ↗
Nov 13, 2026A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Me…
NCT07047118 · Prostatic Cancer, Castration-Resistant
JSB462, AAA617
NVS
Novartis Pharmaceuticals
Phase 2Active, not recruiting138Jul 16, 2027Registry ↗
Nov 13, 2026An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patie…
NCT06991556 · Metastatic Hormone-sensitive Prostate Cancer
JSB462, Abiraterone
NVS
Novartis Pharmaceuticals
Phase 2Active, not recruiting168Dec 3, 2026Registry ↗
Nov 13, 2026Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
NCT06858332 · Atherosclerotic Cardiovascular Disease
Atorvastatin, Simvastatin
NVS
Novartis Pharmaceuticals
—Recruiting2,382Sep 30, 2027Registry ↗
Nov 13, 2026Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081 · Early Breast Cancer
Ribociclib, Letrozole
NVS
Novartis Pharmaceuticals
Phase 3Active, not recruiting1,466Sep 7, 2029Registry ↗
Nov 13, 2026A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced…
NCT05462873 · Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
QEQ278
NVS
Novartis Pharmaceuticals
Phase 1Terminated30Jan 26, 2026Registry ↗
Nov 13, 2026A Registry of Patients With Moderate to Severe Plaque Psoriasis
NCT02786186 · Psoriasis
Secikinumab
NVS
Novartis Pharmaceuticals
—Completed2,376Jan 22, 2026Registry ↗
Nov 12, 2026A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fract…
NCT07465653 · Heart Failure With Reduced Ejection Fraction
HJB647 low dose, HJB647 high dose
NVS
Novartis Pharmaceuticals
Phase 1Recruiting12Dec 8, 2026Registry ↗
Nov 12, 2026Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Phila…
NCT07387926 · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acut…
Asciminib Adult formulation, Asciminib Pediatric formulation
NVS
Novartis Pharmaceuticals
Phase 1/2Recruiting50Sep 19, 2033Registry ↗
Nov 12, 2026An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Ver…
NCT06894511 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
AAA617, ARPI: Abiraterone
NVS
Novartis Pharmaceuticals
Phase 2Active, not recruiting7Nov 17, 2026Registry ↗
Nov 12, 2026Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppu…
NCT06785675 · Hidradenitis Suppurativa
Secukinumab
NVS
Novartis Pharmaceuticals
—Completed
was active, not recruiting
63Jul 16, 2026Registry ↗
Nov 12, 2026ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT06733922 · Relapsing Remitting Multiple Sclerosis (RRMS)
ETNATM-ProgMS
NVS
Novartis Pharmaceuticals
Phase 4Recruiting224Mar 31, 2029Registry ↗
Nov 12, 2026An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356 · Hematologic Malignancy, Solid Tumor
Pelabresib, Ruxolitinib
NVS
Novartis Pharmaceuticals
Phase 3Recruiting50Dec 31, 2029Registry ↗
Nov 12, 2026Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
NCT05795140 · Atypical Hemolytic Uremic Syndrome
Iptcaopan 200 mg
NVS
Novartis Pharmaceuticals
Phase 3Recruiting65Jul 16, 2032Registry ↗
Nov 12, 2026Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Throm…
NCT05653349 · Primary Immune Thrombocytopenia (ITP)
Ianalumab, Placebo
NVS
Novartis Pharmaceuticals
Phase 3Active, not recruiting226Oct 29, 2026Registry ↗
Nov 12, 2026Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/…
NCT05268289 · Lupus Nephritis
Iptacopan (part 1), Iptacopan (part 2)
NVS
Novartis Pharmaceuticals
Phase 2Terminated81Mar 19, 2026Registry ↗
Nov 12, 2026Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multip…
NCT05156281 · Relapsing Multiple Sclerosis
Remibrutinib, Teriflunomide
NVS
Novartis Pharmaceuticals
Phase 3Active, not recruiting1,007Jul 22, 2026Registry ↗
Nov 12, 2026Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refra…
NCT02962414 · Tuberous Sclerosis Complex
everolimus
NVS
Novartis Pharmaceuticals
Phase 3Active, not recruiting206Feb 26, 2027Registry ↗
Nov 10, 2026A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor…
NCT07928037 · Metastatic Castration-Resistant Prostate Cancer
NVS
Novartis Pharmaceuticals
—Not yet recruiting2,045Nov 25, 2026Registry ↗
Nov 10, 2026A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
NCT07855276 · Hidradenitis Suppurativa
LOU064, Placebo
NVS
Novartis Pharmaceuticals
Phase 1Recruiting30Nov 29, 2027Registry ↗
Nov 10, 2026A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abe…
NCT07737756 · Spinal Muscular Atrophy
NVS
Novartis Pharmaceuticals
—Not yet recruiting6Feb 28, 2027Registry ↗
Nov 10, 2026A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Ad…
NCT07681271 · Papulopustular Rosacea
LOU064, Placebo
NVS
Novartis Pharmaceuticals
Phase 2Recruiting100Dec 7, 2027Registry ↗
Nov 10, 2026A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf…
NCT07681258 · Chronic Myeloid Leukemia
NVS
Novartis Pharmaceuticals
—Not yet recruiting80Sep 1, 2027Registry ↗
Nov 10, 2026A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Dos…
NCT07604324 · Dermatitis, Atopic
DCY636, Placebo
NVS
Novartis Pharmaceuticals
Phase 1Recruiting63Jan 27, 2028Registry ↗
Nov 10, 2026A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Establ…
NCT07454889 · Hidradenitis Suppurativa
NVS
Novartis Pharmaceuticals
—Not yet recruiting34Oct 30, 2027Registry ↗
Nov 10, 2026A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leuke…
NCT07454850 · Leukemia, Myeloid, Chronic-Phase
NVS
Novartis Pharmaceuticals
—Not yet recruiting400Jul 2, 2027Registry ↗
Nov 10, 2026Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074 · Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chroni…
Asciminib single agent
NVS
Novartis Pharmaceuticals
Phase 2Recruiting50Feb 23, 2033Registry ↗
Nov 10, 2026Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model i…
NCT07249463 · Cryptosporidiosis
Cryptosporidium parvum oocysts (ABO809), EDI048
NVS
Novartis Pharmaceuticals
Phase 2Recruiting80Mar 23, 2027Registry ↗
Nov 10, 2026Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Par…
NCT07235059 · Chronic Kidney Disease
OJR520, Placebo
NVS
Novartis Pharmaceuticals
Phase 1Recruiting112Jan 21, 2028Registry ↗
Nov 10, 2026EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelis…
NCT06997588 · PIK3CA-related Overgrowth Spectrum (PROS)
Alpelisib
NVS
Novartis Pharmaceuticals
Phase 2Recruiting140Jan 29, 2029Registry ↗
Nov 10, 2026A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600 · Chagas Disease
LXE408, Placebo
NVS
Novartis Pharmaceuticals
Phase 2Recruiting130Jul 22, 2027Registry ↗
Nov 10, 2026A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in…
NCT06439082 · Sickle Cell Disease
Crizanlizumab, Placebo
NVS
Novartis Pharmaceuticals
Phase 3Recruiting354Jul 2, 2029Registry ↗
Nov 10, 2026A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated…
NCT06019637 · Spinal Muscular Atrophies
Onasemnogene Abeparvovec
NVS
Novartis Pharmaceuticals
—Recruiting50Jan 2, 2042Registry ↗
Nov 10, 2026A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
NCT06006559 · Dengue
EYU688, Placebo
NVS
Novartis Pharmaceuticals
Phase 2Recruiting108Jul 22, 2027Registry ↗
Nov 10, 2026An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQ…
NCT05900141 · Hyperlipoproteinemia (a)
Pelacarsen
NVS
Novartis Pharmaceuticals
Phase 3Terminated
was active, not recruiting
41Oct 15, 2026Registry ↗
Nov 10, 2026A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide…
NCT05776927 · Asthma
QVM149, Salmeterol Xinafoate / Fluticasone Propionate
NVS
Novartis Pharmaceuticals
Phase 3Recruiting188Dec 30, 2028Registry ↗
Nov 10, 2026Kesimpta (Ofatumumab) Pregnancy Registry
NCT05634967 · Multiple Sclerosis, Pregnancy
Kesimpta
NVS
Novartis Pharmaceuticals
—Recruiting725Feb 28, 2033Registry ↗
Nov 10, 2026A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Vers…
NCT05562466 · Asthma
QMF149, Budesonide
NVS
Novartis Pharmaceuticals
Phase 3Recruiting200Feb 1, 2028Registry ↗
Nov 10, 2026Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malign…
NCT05541341 · Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
tisagenlecleucel
NVS
Novartis Pharmaceuticals
—Recruiting200Nov 23, 2037Registry ↗
Nov 10, 2026Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children…
NCT05222529 · Asthma
Glycopyrronium bromide 25ug, Placebo
NVS
Novartis Pharmaceuticals
Phase 2Recruiting42Jul 30, 2027Registry ↗
Nov 10, 2026Dabrafenib and/or Trametinib Rollover Study
NCT03340506 · Melanoma, Non Small Cell Lung Cancer
dabrafenib, trametinib
NVS
Novartis Pharmaceuticals
Phase 4Recruiting100Dec 28, 2032Registry ↗
Nov 9, 2026A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable S…
NCT07908680 · Schizophrenia
XEP527, Placebo
NVS
Novartis Pharmaceuticals
Phase 1Recruiting
was not yet recruiting
36Mar 6, 2028Registry ↗
Nov 9, 2026Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Ch…
NCT07816328 · Chronic Spontaneous Urticaria
Remibrutinib, Omalizumab
NVS
Novartis Pharmaceuticals
Phase 3Recruiting382May 24, 2028Registry ↗
Nov 9, 2026A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With S…
NCT07811869 · Chronic Pruritus of Unknown Origin
Remibrutinib, Placebo
NVS
Novartis Pharmaceuticals
Phase 3Recruiting180Feb 26, 2029Registry ↗
Nov 9, 2026A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to…
NCT07801495 · Moderate to Severe Psoriatic Arthritis
DDY391, Placebo
NVS
Novartis Pharmaceuticals
Phase 2Recruiting220Dec 13, 2028Registry ↗
Nov 9, 2026A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Mo…
NCT07775924 · Cutaneous Lichen Planus
Placebo, GIA632
NVS
Novartis Pharmaceuticals
Phase 2Recruiting259Nov 22, 2028Registry ↗
Nov 9, 2026A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371 · IgE-Mediated Food Allergy, Peanut Allergy
Remibrutinib, Placebo
NVS
Novartis Pharmaceuticals
Phase 3Recruiting576Mar 30, 2029Registry ↗
Nov 9, 2026A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXA…
NCT07748624 · VEXAS Syndrome
Arumakimig, Placebo
NVS
Novartis Pharmaceuticals
Phase 2Recruiting120Dec 26, 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:22 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances